Browse
Submit Data
Databases
API
Help

Dataset Information

17 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

ABSTRACT: RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

DISEASE(S): Lung Cancer,Melanoma,Colorectal Cancer,Colorectal Neoplasms,Melanoma (skin),Pancreatic Cancer,Breast Neoplasms,Pancreatic Neoplasms,Lung Neoplasms,Breast Cancer

PROVIDER: 2077830 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

DNA methylation analysis in malignant melanoma clinical samples [EPIC array]

Project description:Comprehensive DNA methylation analysis in malignant melanoma clinical samples and primary melanocyte culture. Infinium MethylationEPIC BeadChip was used to obtain DNA methylation profiles. Samples included 8 malignant melanoma cases and primary melanocyte culture.

2020-10-22 | GSE140170 | GEO

DNA methylation analysis in malignant melanoma clinical samples [450K array]

Project description:Comprehensive DNA methylation analysis in malignant melanoma clinical samples. Infinium HumanMethylation450 BeadChip was used to obtain DNA methylation profiles across 485,577 CpG sites. Samples included 54 malignant melanoma cases and primary melanocyte culture.

2020-10-22 | GSE140169 | GEO

Melanoma Cancer miRNA Blood Profiles

Project description:This project analyzes peripheral blood profiles of melanoma cancer patients. Since miRNAs are known to be valuable diagnostic markers we asked whether respective patterns of melanoma patients can be detected in peripheral blood samples rather than in biopsies. The project aimed at an improved understanding of complex profiles rather than single markers. Thus, a high-throughput technique was necessary, profiling all known miRNAs integratively. Top markers have been validated by using qPCR. n = 22 normal controls and n = 35 melanoma cancer samples have been screened for the complete miRNA repertoire. The melanoma samples have been collected by two clinicians using the same procedure. Please note that each miRNA has been measured in seven replicates and the median of the replica has been computed.

2010-06-23 | E-GEOD-20994 | biostudies-arrayexpress

DNA methylation analysis in malignant melanoma clinical samples

Project description:DNA methylation analysis in malignant melanoma clinical samples

| PRJNA588464 | ENA

Melanoma Cancer miRNA Blood Profiles

2010-03-23 | GSE20994 | GEO

DNA methylation analysis in malignant melanoma clinical samples [EPIC array]

Project description:DNA methylation analysis in malignant melanoma clinical samples [EPIC array]

| PRJNA588465 | ENA

DNA methylation analysis in malignant melanoma clinical samples [450K array]

Project description:DNA methylation analysis in malignant melanoma clinical samples [450K array]

| PRJNA588466 | ENA

Affymetrix CytoScan HD and OncoScan array data for malignant melanoma samples

Project description:Malignant melanoma is a highly metastatic disease disseminating to several distant sites. This potential is also of great clinical impact for patient survival and therapeutic success. Knowledge about melanoma genomics is mainly based on lymphatic or skin metastases derived data, whereas data from distant sites is rather limited. Therefore, an autopsy-based visceral metastasis biobank was established and an array-based CNV analysis was performed focusing primarily on major organs (brain, lung and liver) on a total of 38 samples (10 primary and 28 organ metastasse). A unique picture emerged about organ specific CNV type distributions or gene alterations including the frequent loss of DNA damage error genes in brain metastases, the presence of HGF/MET autocrine loop in brain and lung metastases, the traces of immunogenic mimicry exclusive for lung metastases or the correlation of BRAF copy number and mutant allele frequency especially in lung metastases. All these above phenomena have a great influence on therapy efficacy or resistance.

2021-12-15 | GSE185165 | GEO

Proteome profiling of plasma from patients with lung adenocarcinoma and malignant melanoma.

Project description:Here, we have reported the plasma proteomes of 6 malignant melanoma (MM) and 6 lung adenocarcinoma (LUAD) patients, generated using HiRIEF pre-fractionation and tandem mass tags (TMT)-based peptide quantification. We have detected traditional plasma marker proteins, as well as many LUAD and MM related proteins in the cancer plasma. Our advanced proteomics workflow exhibits high proteome coverage for both plasma and plasma derived extracellular vesicles (pEVs), providing the ability to detect potential disease-specific markers in pEVs enriched from clinical plasma samples.

2024-08-15 | PXD039338 | Pride

Copy number analysis in melanoma tumor samples from E2603

Project description:Blinded study, melanoma tumor samples from patients treated with carboplatin and paclitaxel +/- sorafenib are compared aCGH of human melanoma tumor samples

2015-10-10 | GSE73899 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data